Approximately 25% of B cell-precursor ALL cases are characterized by a balanced t(12;21) chromosomal translocation that creates the ETV6-RUNX1 fusion gene, conferring a favorable prognosis 1 . This particular disease has shaped understanding of the development of cancer well beyond leukemia, illuminating the long latency between initiating genetic lesion and clinically overt disease, the patterns of cooperativity among oncogenic mutations and the complex evolutionary trajectories a cancer can follow. Monozygotic twin studies with concordant ALL and 'backtracking' studies using archived neonatal blood spots established that the translocation generating ETV6-RUNX1 is an initiating event occurring prenatally in a committed B cell progenitor 2 . However, the fusion gene is not sufficient on its own to cause overt leukemia, and a number of studies have now provided strong evidence that additional mutations are essential for the development of ALL 3 . Twin studies confirm that these additional events are most likely postnatal and secondary to the ETV6-RUNX1 fusion 4 .
A r t i c l e s
Approximately 25% of B cell-precursor ALL cases are characterized by a balanced t(12;21) chromosomal translocation that creates the ETV6-RUNX1 fusion gene, conferring a favorable prognosis 1 . This particular disease has shaped understanding of the development of cancer well beyond leukemia, illuminating the long latency between initiating genetic lesion and clinically overt disease, the patterns of cooperativity among oncogenic mutations and the complex evolutionary trajectories a cancer can follow. Monozygotic twin studies with concordant ALL and 'backtracking' studies using archived neonatal blood spots established that the translocation generating ETV6-RUNX1 is an initiating event occurring prenatally in a committed B cell progenitor 2 . However, the fusion gene is not sufficient on its own to cause overt leukemia, and a number of studies have now provided strong evidence that additional mutations are essential for the development of ALL 3 . Twin studies confirm that these additional events are most likely postnatal and secondary to the ETV6-RUNX1 fusion 4 .
The genome of ETV6-RUNX1 ALL has been well characterized at the copy number and cytogenetic level. Array-based genome-wide profiling studies have shown copy number aberrations (CNAs) to be common, mostly comprising deletions and affecting genes involved in B-lymphocyte development and differentiation 5 , such as CDKN2A, PAX5, BTG1, TBL1XR1, RAG1, RAG2 and the wild-type copy of ETV6. The presence of V(D)J recombination sequence motifs close to these CNAs has suggested a role for aberrant RAG endonuclease targeting at these loci [6] [7] [8] [9] [10] , but these studies have been limited to the analysis of a small number of annotated breakpoints at specific genes.
To obtain a detailed portrait of the composite genetic events that, in concert with the ETV6-RUNX1 fusion gene, drive this subtype of ALL, we carried out genomic analysis of diagnostic samples from RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia whole-genome sequencing of both diagnostic and remission samples to 50× average sequence coverage. PCR for the IGH rearrangement showed that all samples in the study had rearranged V(D)J loci, with oligoclonality observed in most cases 11 (Supplementary Table 1 ).
In addition to the fusion gene, we confirmed 523 structural variations (average of 11 per case; range of 0-49) in 44 of the samples in the study (Fig. 1a) : 417 were intrachromosomal, and 106 were interchromosomal (Supplementary Table 4) , with 76% of intrachromosomal rearrangements being deletions. We identified 779 somatic substitutions and 16 indels across 715 protein-coding genes and 3 microRNAs (Fig. 1b and Supplementary Table 6 ). Each sample had on average 14 coding point mutations (range of , consistent with the low number of acquired somatic mutations reported in hematological cancers and childhood malignancies. lo id E T P B r e a s t B r e a s t P a n c r e a s P a n c r e a s P r o s t a t e P r o s t a t e E T P 
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Structural variations bear the hallmarks of RAG activity During lymphocyte development, cells undergo somatic recombination, also known as V(D)J recombination, at the variable immunoglobulin and T cell receptor loci 12 . This process is primarily mediated by the RAG endonucleases RAG1 and RAG2, which are targeted to V(D)J sites by recombination signal sequence (RSS) motifs consisting of a highly conserved heptamer (CACAGTG) and a less conserved nonamer (ACAAAAACC) separated by a 12-bp or 23-bp sequence-independent spacer 13 . RAG endonucleases bind DNA at RSS motifs and cleave DNA at the boundary between the RSS and the flanking coding sequence, thereby generating two blunt and two hairpin ends that are held in close proximity to each other by the RAG complex 13 . Processing of these ends often involves the addition of non-templated sequence (NTS) at the breakpoint by terminal deoxynucleotidyl transferase (TdT) in a process that results in further diversification of the V(D)J locus 14 . Functioning heptamers or nonamers outside the context of a conserved RSS, open chromatin state, trimethylation at histone H3 lysine 4 (H3K4me3), non-B DNA sequence and deaminated methyl CpGs are all genomic conformations that have been associated with alternative mechanisms of RAG recruitment, targeting of DNA breaks, breakpoint localization and subsequent genomic rearrangement 6, 15, 16 . Clustering of deletion breakpoints adjacent to RSS sites or motifs approximating the conserved RSS DNA sequence 17 in lymphoid genes has provided some evidence of off-target RAG activity in leukemias [6] [7] [8] [9] [10] 18 .
However, the association between breakpoints and RSS motifs has not been systematically evaluated on a genome-wide basis.
We resolved 354 of 523 structural variations to base-pair resolution, generating the largest such data set in ALL by some margin (Supplementary Table 4) , and searched for the conserved RSS motif (Supplementary Fig. 1 ), proposed AID recognition motifs 16 and the presence of CpGs at breakpoint sites ( Supplementary Fig. 2 ) using a bespoke algorithm. As a positive control, we used 26 structural rearrangements at the IGH and TCR loci, representing canonical RAG sites (Fig. 1c, Supplementary Fig. 1a-c and Supplementary Table 7) . To confirm that our findings were specific to ALL, we also evaluated two published ALL data sets (hypodiploid ALL and early T-progenitor ALL) 10, 19 and made comparisons to published rearrangements from breast, pancreatic and prostate cancers (Fig. 1c,d ) [20] [21] [22] .
Conserved RSS motifs were computationally detected (RSS score ≥ 8.55) in 23 of the 26 positive-control rearrangements ( Fig. 2a and Supplementary Table 7 ) and 44 of the 354 somatic structural variations outside of V(D)J sites (Fig. 2b, Supplementary Fig. 1d-f and Supplementary Table 4) . As expected, canonical V(D)J RSS signals were characterized by deletions and inverted intrachromosomal rearrangements (Fig. 1c) , and, in 92% (24/26), we observed NTS at the breakpoint junction (Supplementary Table 7 ). Enrichment for RSS motifs was particularly striking for genomic deletions in ETV6-RUNX1 ALL (Fig. 1c) 23 on 354 resolved breakpoints, analyzing the 20 bp of sequence spanning each breakpoint junction. We discovered 2 significant motifs by this analysis: (i) the first 6 bases (underlined) of the perfect heptamer sequence CACAGTG (E value = 9.9 × 10 −81 ) 23 , identified across 159 breakpoint junctions ( Fig. 2c and Supplementary  Fig. 1g-i) , and (ii) the first 4 bases of the heptamer sequence, the CACA tetranucleotide (E value = 4.9 × 10 −2 ) (Supplementary Table 8 ), identified adjacent to 5 rearrangements. As both of these motifs (CACAGT and CACA) correspond to the most conserved portion 17 of the RSS heptamer sequence, all breakpoints reporting either of these motifs were annotated as 'RSS-like' .
Overall, in 140 of 354 rearrangements (39.5%), we found convincing signatures of RAG recognition sequence motifs at one or both ends ( Supplementary Fig. 3 ) of the breakpoint junction. The overwhelming majority of cases studied had at least one structural variation with an RSS or heptamer signal, and most had several such variants. An equivalent analysis of breakpoints from breast cancers 20 , pancreatic cancers 21 and prostate cancers 22 did not show any evidence of RSS motifs at breakpoint junctions (Fig. 1c) , nor was the heptamer motif identified at junctions (Supplementary Table 8 ). We did not observe specific enrichment of CpGs or any of the proposed AID recognition motifs 16 at breakpoint junctions in ETV6-RUNX1 ALL relative to other cancers ( Supplementary Fig. 2 and Supplementary Table 9 ).
The other feature of canonical RAG-mediated V(D)J rearrangement is the inclusion of NTS at the breakpoint. All 44 rearrangements with a near-perfect RSS motif and 73 of the 96 rearrangements with a heptamer motif had novel sequence inserted at the breakpoints, suggestive of TdT activity during the formation of breakpoint junctions. Of the 354 resolved breakpoints overall, 248 (70%) had inserted NTS, 79 (22.4%) showed evidence of base-pair homology between the 2 breakpoints, and 27 (7.9%) involved blunt-end breakpoints ( Supplementary Fig. 4 ). This data set shows a marked increase in breakpoints characterized by the inclusion of NTS relative to breakpoints identified in breast cancer, pancreatic cancer and prostate cancer (with frequencies of NTS inclusion of 16.2% (n = 193), 19% (n = 36) and 6.7%
(n = 395), respectively; P < 2.2 × 10 −16 ; Fig. 1d ). Other mechanisms of genomic rearrangement were occasionally observed, including chromothripsis 24 and chains of rearrangements similar to those reported in prostate cancer 25 (Supplementary Fig. 5 ).
Chromatin signatures at structural variation sites
To explore underlying genomic features that influence the distribution of genomic rearrangements, we examined whether there was any enrichment of particular chromatin states at the 523 structural variations identified. For this analysis, we considered the 15 chromatin states defined by the Encyclopedia of DNA Elements (ENCODE) Project 26 . We found that structural variants in ETV6-RUNX1 ALL showed up to 14-fold enrichment of active promoter and enhancer regions relative to the other chromatin states (P < 2.2 × 10 −16 ; Fig. 3a ). This enrichment was particularly pronounced for structural variations that had an RSS-like motif: for example, deletions with RSS-like sequences showed 33-fold enrichment of active promoter regions (P < 2.2 × 10 −16 ; Fig. 3a) . Overall, in our study, 30% of resolved rearrangements mapping in close proximity to an RSS-like motif occurred in promoter sites, 14% occurred in enhancer sites, and 13% occurred in sites of transcription (Supplementary Table 10 ).
The relationship between rearrangements and chromatin state observed in ETV6-RUNX1 genomes was significantly different (P < 2.2 × 10 −16 ) from that expected by chance. Structural variations reported in a recent analysis of 40 individuals with hypodiploid ALL 10 were also significantly different from the null distribution 
. S t r o n g
e n h a n c e r 5 . S t r o n g e n h a n c e r 6 . W e a k e n h a n c e r 7 . W e a k e n h a n c e r 8 . I n s u la t o r 9 . T r a n s c r ip t io n t r a n s it io n 1 0 . T r a n s c r ip t io n e lo n g a t io n 1 1 . W e a k t r a n s c r ip t io n 1 2 . R e p r e s s e d 
npg
A r t i c l e s (P < 2.2 × 10 −16 ; Supplementary Fig. 6 ), with structural variations mapping close to RSSlike sequences also showing a preponderance for promoter and enhancer sites (13-fold and 17-fold enrichment, respectively). In contrast, breast cancer structural variations showed a rather uniform distribution across the 15 chromatin states, with modest but statistically significant enrichment in gene footprint regions (P < 2.2 × 10 −16 ), as previously described 27 , but not in promoters or enhancers (Supplementary Fig. 6 ).
The inferred chromatin states in ENCODE data derive from a combinatorial code of individual histone modifications. We therefore explored whether specific histone marks or transcription factor binding sites (Supplementary Table 11 ) were associated with genomic rearrangements in ETV6-RUNX1 ALL. We found significant correlation of rearrangement positions with peaks of H3K4me3, a marker of active promoters (q = 0.02; Supplementary Fig. 7 ). This finding is particularly notable because the PHD finger of the RAG2 protein has been shown to bind H3K4me3 (ref. 28) , which would explain why this mutational process so precisely targets regions residing within active promoters and enhancers.
Localized clustering of deletions close to RSS-like motifs
Tight clustering of deletions next to RSS-like sequences 9 as well as reiterated CNAs in diagnostic ALL samples 29 has previously been reported. We identified 14 clusters of at least 2 deletions (range of 2-6) with breakpoints in close proximity to each other as well as to the heptamer motif ( Fig. 3b-d) . For example, in four samples with deletions at 9p21.3, the deletion breakpoints were spaced 0 to 8 bp from each other and were in close proximity to an RSS-like sequence ( Fig. 3b and Supplementary Table 12) . Consistent with the preceding analysis, these breakpoint clusters frequently coincided with gene promoters (Fig. 3b-d and Supplementary Fig. 8 ).
Within each locus, deletions that did not satisfy our criteria for annotation as having RSS-like sequences were observed to cluster with structural variations that did have a nearby RSS motif ( Fig. 3d and Supplementary Table 12 ). Not unexpectedly, the genes disrupted in these clustered and reiterated deletions are among the most frequently targeted in ALL, including CDKN2A, BTG1, TBL1XR1, RAG1, RAG2 and BTLA [8] [9] [10] 19, 29 .
These data emphasize the targeted nature of the RAG-mediated mutational process. Not only is there enrichment of structural variants in active promoter and enhancer regions across the genome, but there is also a striking propensity for breakpoints to cluster within very specific ranges in individual promoter or enhancer elements. 
Clonal heterogeneity of RAG-mediated deletions
Massively parallel sequencing data enable estimation of the proportion of tumor cells carrying a mutation on the basis of the fraction of sequencing reads reporting a variant allele 20 . To study the clonal complexity of ETV6-RUNX1 ALL, we calculated variant allele fractions for all mutations identified by exome sequencing (Supplementary Table 6 ). We found extensive clonal heterogeneity across most cases in the study (Fig. 4a) , confirming previous findings that multiple subclones coexist at presentation in individuals with ETV6-RUNX1 ALL 7, 29 .
To assess the timing of aberrant RAG-mediated deletions, we used a single-cell genotyping protocol 30 in two cases ( Table 1 and Supplementary Fig. 9 ). For PD3958a, we interrogated 143 cells for the fusion gene, 3 genomic deletions and 3 acquired missense mutations ( Fig. 4b and Supplementary Table 13 ). For PD3971a, we genotyped 159 cells for the fusion gene, deletions at 1q31 and 12p13.2-p12.3 and 4 point mutations (Fig. 4c and Supplementary Table 14) . With the exception of the deletion at 12p13, all deletions studied carried an RSS signature.
Using the single-cell data, we reconstructed partial phylogenies of tumor evolution for the two cases (Fig. 4b,c) . In these phylogenies, we found (i) that the ETV6-RUNX1 fusion gene was always in the trunk of the phylogenetic tree, as expected for an initiating lesion; (ii) that point mutations could be either clonal or subclonal, showing good correlation between the observed variant allele fraction in exome data and the fraction of single leukemia cells reporting the variant (Table 1) ; and (iii) that, in both cases, the RAG-mediated deletions were located in both the trunk of the phylogenetic tree and in subclonal branches.
These data suggest that RAG-mediated genomic instability in ETV6-RUNX1 ALL was an ongoing mutational process in these two cases. Intriguingly, the RAG1-RAG2 locus on chromosome 11p12 is itself a frequent target of deletion (Supplementary Table 4) . NTS was present in four of the five resolved structural variations, and, in three, there was evidence of an RSS signature, suggesting that the RAG complex mediated its own deletion. Samples with 11p12 deletions did not differ in either the total number of observed structural variations or in the total number of RAG-mediated structural variations (Fig. 5a) . The deletions we observed were heterozygous, and it is therefore unclear what selective benefit, if any, might accrue to a clone from deleting this locus.
Structural variations show high fraction of recurrent events
Classically, in cancer genomics, high rates of recurrence for a given event are used to distinguish mutations that are likely to be oncogenic from passenger variants. Restricting our analysis to deletions, we evaluated whether the consequence of each structural variation for gene copy number was recurrent in ALL or overlapped with genes showing recurrent copy number loss or inactivation by point mutation in other cancers (Supplementary Table 4) . Overall, of 310 eligible deletions (Supplementary Table 4) , 151 satisfied these criteria, accounting for 49% of deletions in the study. Each sample carried on average 3 (n = 3.4) CNAs that involved genes previously reported to be inactivated in cancer or recurrently affected by CNAs in ETV6-RUNX1 ALL (Fig. 5b,c and Supplementary  Table 4) . That half of deletions are recurrent is a rather remarkable figure.
This markedly non-random distribution of mutations has substantial implications for the identification of cancer-related genes in ALL. Typically, the background distribution of mutations is assumed to be uniform. With this RAG-mediated mechanism, however, passenger rearrangements would also cluster in actively transcribed genes and would consequently mimic true cancer-related genes. In this setting, the best approach to distinguish true cancer genes from genes affected by clustered passenger rearrangements would be to find enrichment of truncating point mutations in the same gene. This type of mutation has, for example, been observed in PAX5 and CDKN2A in ALL 31 . Thus, exome sequencing in ALL is an important confirmatory step in defining new cancer-relevant genes.
Integrative genome and exome analysis identifies new ALL genes
Integrative analysis of exome and whole-genome data identified 694 genes recurrently affected by CNAs, chromosomal rearrangements and/or acquired mutations (Supplementary Table 15) . The most frequent and recurrent somatic alterations that we identified in the present study involved deletion or mutation of ETV6, BTG1, TBL1XR1, PAX5, CDKN2A, NR3C2, RAG2 and BTLA, all loci previously described by cytogenetic or copy number profiling 
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A r t i c l e s studies (Fig. 6a) 5 . Of these genes, ETV6, BTG1 and TBL1XR1 all had an inactivating point mutation (nonsense, frameshift or splice site), and such mutations have previously been found in PAX5, CDKN2A and ETV6, suggesting that they are bona fide ALL genes. We note that the majority of these inactivating point mutations and genomic rearrangements were heterozygous, suggesting that haploinsufficiency of leukemia suppressor genes might frequently be operative in ETV6-RUNX1 ALL. A systematic evaluation of all genes affected by both structural variation and mutation identified three previously unreported genes that would not have been highlighted by either data set alone. ATF7IP encodes a nuclear protein that, through interaction with MBD1 and SETDB1, mediates heterochromatin formation and transcriptional repression. ATF7IP maps to 12p13.1 and is located 2.7 Mb centromeric to ETV6, which is a target of frequent deletions 32 . In our study, eight of the nine cases with 12p13 deletions had concomitant deletions in both genes. One case, however, had a focal deletion at 12p13.1 targeting only ATF7IP (Fig. 6b) . Furthermore, exome sequencing analysis identified two additional samples with ATF7IP mutations, including one inactivating nonsense mutation (encoding p.Arg363*) and one missense mutation (encoding p.Arg571Gln) that alters the likely nuclear localization signal, maps within the SETDB1 interaction domain and is predicted to be deleterious (Supplementary Table 6 ). Additional evaluation of existing SNP6 array data from 21 ETV6-RUNX1 ALL cases at diagnosis and relapse 33 identified 10 samples with deletions extending to both genes, 7 cases with ETV6-only deletions and 1 case with an independent ATF7IP deletion acquired at relapse (Supplementary Table 16 ). ETV6 and ATF7IP are two of the most commonly mutated genes in ETV6-RUNX1 ALL, and, although they are both deleted in ~67% of the 12p13 deletions, the present study provides evidence of an independent role for ATF7IP mutations in ETV6-RUNX1 ALL pathogenesis.
MGA encodes a transcription factor that regulates the expression of Max network and T-box family target genes, including MYC 34 . We identified deletions mapping to 15q14-q15.2 resulting in loss of MGA in two cases (PD3971a and PD3951a). In addition, we identified a frameshift nonsense mutation (encoding p.Asp187fs*46) in PD4026a and a missense mutation (encoding p.Ser162Phe) in PD4010a mapping within the DNA-binding domain. STAG2 is a component of the cohesin complex, which is often inactivated by mutations in myeloid leukemias 35 and has recently been observed in chromosomal translocations in T-cell ALL 36 . In our study, STAG2 was mutated in five cases: three had interchromosomal rearrangements between Xq25 and chromosomes 6 and 9, and PD4018a and PD4031a harbored focal intronic deletions of unclear consequence. We also identified a STAG2 missense mutation (encoding p.Arg344Lys) in PD4022a. 
A r t i c l e s
we identified a nonsense mutation in SMC1A and a missense mutation in SMC5, which encode two additional components of the cohesin complex (Fig. 6a) . Exome sequencing analysis identified 795 somatic mutations mapping to 719 genes, with 36 genes carrying recurrent non-silent mutations in at least 2 cases each. Of these genes, only three (KRAS, NRAS and SAE1) were mutated significantly more than expected by chance, as was recently reported for hotspot mutations in WHSC1 (NSD2) (Supplementary Table 6 ) 37 . Notably, 34 of the genes reported in the present study were enriched for inactivating mutations across the 7,651 cancers (Supplementary Table 17 ). Of these, the most significant genes are well-recognized tumor suppressors such as CDKN2A, CDKN2B, NF1, KMT2D (MLL2), ARID2, TP53, RB1, APC, SETD2, KDM6A, CTCF, ARID1B, FBXW7 and BCOR. This heterogeneity underscores the biological complexity present even within a well-defined subtype of ALL.
Mutational signatures in ETV6-RUNX1 ALL
Analysis of the nucleotide composition of each mutation and the sequence context in which it occurred identified two main mutational signatures: C>T transitions at CpGs and C>G and C>T mutations at TpCs, contributing 56% and 32% of all substitutions, respectively (Fig. 7a) . The number of C>T mutations at CpGs significantly correlated with age at diagnosis (r 2 = 0.62, P = 1.6 × 10 −5 ), whereas C>T mutations at TpCs did not. C>T substitution at a methylated cytosine is the most widespread mutational process in genome evolution and cancer.
The second most frequent process involved transitions and transversions at cytosines in a TpC context. This process was observed in 36 of the samples sequenced (64%) and was the predominant signature in the 3 samples with the most acquired mutations (Fig. 7a) . This signature is mostly represented by TpCpW sites (where W = A or T) (Supplementary Fig. 10 ) and is consistent with the reported preference of the APOBEC family of enzymes for cytosine deamination to uracil 38, 39 . This process has recently been proposed as a likely mechanism underlying clusters of localized somatic hypermutation (kataegis) in breast and other cancers 20, 40, 41 .
To explore this signature, we performed high-depth whole-genome sequencing in PD4020a. Whole-genome sequencing analysis identified 7,948 high-confidence substitutions and 122 indels ( Supplementary  Tables 18 and 19) . Strikingly, 94% of the substitutions were C>G or C>T changes at TpC sites (Fig. 7b,c) . We identified 19 clusters of 6 or more mutations present on the same strand 40 (Fig. 7d, Supplementary  Fig. 11 and Supplementary Table 18 ). Kataegis in breast cancer often colocalizes with structural rearrangement. However, such colocalization was not observed in PD4020a, where no structural variation mapped within 5 kb of any mutation cluster.
DISCUSSION
The present study has provided a detailed characterization of the genomic architecture of 57 individuals with ETV6-RUNX1 ALL. We observe a paucity of recurrent coding-region mutations and a scarcity of the kinase mutations that are common in highrisk subtypes of ALL 42 . Genomic rearrangement emerges as the predominant driver of this disease. In a large proportion of the structural variations characterized, we identify RAG recognition sequences near the breakpoint junctions, evidence of TdT activity, and enrichment in active promoter and enhancer regions. Our data may underestimate the contribution of RAG-mediated recombination to structural variation in ETV6-RUNX1 ALL. We find a large proportion of structural variations that do not satisfy our criteria for RSS annotation yet follow the same chromatin distribution as the RSS-like structural variations, with strong enrichment at promoters, and exhibit the inclusion of NTS at breakpoint junctions. A proportion of these variations may have been mediated by RSS motifs that were less conserved or more distant than those for which we screened 6, 43 . 
A r t i c l e s
It has previously been proposed that aberrant RAG activity might contribute to leukemogenesis [6] [7] [8] [9] [10] . We note that the presence of full or partial RAG recognition motifs in genes near breakpoints is not in itself evidence of functional competence of these sites, nor is the presence of NTS at breakpoint junctions firm evidence of TdT activity after RAG targeting. Furthermore, TdT can act on DNA breaks caused by mechanisms other than RAG activity 44 . However, the specificity of the genomic profiles observed in ETV6-RUNX1 ALL, coupled with the absence of these motifs near rearrangements from breast, pancreatic and prostate cancer, makes their functional relevance highly probable. There is still much to explore to obtain a detailed understanding of the biochemical relationships linking sequence context, chromatin landscape and RAG activity in ETV6-RUNX1-positive lymphoblasts.
The picture that emerges of ETV6-RUNX1 ALL is one of stalled early B-lineage differentiation 2, 45 . The ETV6-RUNX1 fusion itself arises in either a fetal hematopoietic stem cell or a very early B progenitor 2, 45 , promoting the creation of a covert preleukemic clone with partially stalled passage through the B-precursor developmental compartment 2, 45, 46 . RAG recombinases continue to be highly expressed by ETV6-RUNX1 cells, resulting in diverse and ongoing oligoclonal V(D)J rearrangements 11 . Inactivation of genes that encode transcription factors for B-lineage differentiation would further trap cells within the precursor compartment. These features are not unique to ETV6-RUNX1 ALL, but this subtype, compared with others, does seem to have more extensive IGH rearrangements 6,11 and higher RAG gene expression 47 . It will be interesting to replicate these analyses across the many other subtypes of ALL to evaluate the generality of this mutational process in lymphoblastic leukemia.
URLs. European Genome-phenome Archive, https://www.ebi.ac.uk/ ega/.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Raw sequencing data are available through the European Genome-phenome Archive under accessions EGAD00001000634, EGAD00001000635 and EGAD00001000636. 
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ONLINE METhODS
Samples. The patient samples studied in this investigation were collected from Italian or UK hospitals, with informed consent and local ethical review committee approval (CCR 2285, Royal Marsden Hospital NHS Foundation Trust). Collection and use of patient samples were approved by the appropriate institutional review board (IRB)of each institution. In addition, this study and usage of its collective materials had specific i approval.
Exome capture library construction and sequencing. Matched genomic DNA (3-5 µg) from leukemic samples and samples at full remission from 56 individuals with childhood ALL was prepared for Illumina paired-end sequencing. Exome enrichment was performed using the Agilent SureSelect Human All Exon 50Mb kit (Agilent Technologies). Flow-cell preparation, cluster generation and paired-end sequencing (75-bp reads) were performed according to the Illumina protocol guidelines on an Illumina Genome Analyzer IIx instrument. Target coverage per sample was for 70% of the captured regions at a minimum depth of 30× sequencing coverage. Detailed sequencing metrics are provided in Supplementary Table 5 .
Low-depth whole-genome sequencing. Leukemic DNA (2-5 µg) for 51 cases was prepared for short-insert (300-to 400-bp) library construction flow-cell preparation and cluster formation using the Illumina no-PCR library protocol 48 . We performed 50-base paired-end sequencing on an Illumina Genome Analyzer IIx instrument according to the manufacturer's guidelines. Detailed sequencing metrics statistics are presented in Supplementary Table 3. Variant detection (substitutions). Sequencing reads were aligned to the human genome (NCBI Build 37) using the Burrows-Wheeler Aligner (BWA) algorithm with default settings 49 . We used an in-house algorithm, CaVEMan (Cancer Variants through Expectation Maximization), to identify somatically acquired single-nucleotide substitutions. CaVEMan uses a naive Bayesian approach to estimate the posterior probability of each possible genotype (wild type, germline, somatic mutation) at each base given the reference base and the predefined copy number status and proportion of tumor cells in the sample sequenced. To increase variant specificity, several filters after processing as well as manual curation were applied to the initial set of CaVEMan mutation calls. Briefly, the spectrum of variant allele representation between forward and reverse reads and the range of positions in each read were evaluated as well as regions of low sequencing depth or poor sequence quality as previously described 50 . All substitutions were annotated to Ensembl version 58.
Variant detection (insertions, deletions and complex indels).
To identify indels, we used a modified version of the Pindel 51 algorithm allowing for mapping of split reads using either one or both reads as an anchor and evaluating the second read through a series of split mappings. All putative indel calls were further filtered on the basis of coverage (minimum of three reads supporting a call), orientation (at least one read in each direction must report the call), local sequence context (variant length ≤ 4 within a sequence where the variant motif is repeated up to nine times) and with no more than 5% of normal reads reporting the indel variant. All indels were annotated to Ensembl version 58.
Variant detection (structural variations).
Sequencing reads were mapped to the reference genome. Groups of at least two discordantly mapping pairedend reads by distance or orientation were identified using Brass (Breakpoint via Assembly) 20 . Putative structural variation was selected on the basis of the following criteria:
Groups of discordantly mapping paired-end reads supported by at least three discordant reads; Absence of discordant reads supporting the same variant in a panel of 45 in-house control genomes; Absence of discordantly mapping paired-end reads that showed at least 20% homology on either side of structural variant breakpoints identified in the 1,000 genomes sequenced by the 1000 Genome Project Consortium; Tandem duplications, intrachromosomal events and deletions greater than 1 kb in length;
Absence of an alternative best-mapping solution in the expected read-pair position called using less stringent alignment parameters; Absence of read clustering overlapping one of the paired-read ends in the group indicative of misalignment due to repetitive or recurrent genomic sequences; Groups of discordantly mapping paired-end reads that are supported by segmentation of GC-normalized copy number profiles.
Variant validation (substitutions).
Primers were designed to amplify 300-to 500-bp fragments by conventional PCR for putative single-nucleotide substitutions identified by exome sequencing. PCR amplification was performed for both tumor and remission DNA pairs, and fragments were purified using SPRI bead clean up (Agencourt AMPure XP beads, Beckman Coulter).
A sample-specific 8-bp index tag was incorporated during amplification to allow subsequent deconvolution of sample origin for all recurrent variants. Individual pools of normal and tumor samples were prepared and subjected to 454 pyrosequencing (Roche). Sequencing data were aligned as previously described, and targeted evaluation of sequence reads by chromosome, position and variant base was performed to confirm the somatic status of the reported variants.
Variant validation (indels).
Primers were designed to amplify 300-to 500-bp fragments covering the genomic location of the identified indels. After purification, DNA fragments were sequenced twice using the ABI Dye Terminator Cycle Sequencing kit (Applied Biosystems).
Variant validation (structural variations).
Primers mapping on either end of the reported structural variant in the appropriate orientation were designed and used for conventional PCR amplification on both tumor and remission DNA. PCR runs were performed in duplicate, and amplimers were separated by agarose gel electrophoresis. Conventional Sanger sequencing of amplimers unique to tumor samples enabled breakpoint resolution to the base-pair level. Sanger sequencing-derived sequences were mapped to the reference genome, and genomic breakpoint coordinates were characterized as well as annotated for the presence of microhomology, if homologous sequence was present in the respective 5′ and 3′ ends of the breakpoints, a NTS of one or more nucleotide bases was present in the breakpoint junction that did not map to the reference genome or as clean blunt ends if the two breakpoints were continuous (Supplementary Fig. 3 ).
Copy number and loss-of-heterozygosity analysis. Copy number analysis was performed using ASCAT (version 2.2) 52 , taking into account nonneoplastic cell infiltration and tumor aneuploidy, and resulted in integral allele-specific copy number profiles for the tumor cells. Allele-specific copy number estimates for point mutations and indels were obtained by integrating copy number and sequencing data.
PD4020 variant annotation.
For substitutions in subject PD4020a, we used CaVEMan parameters that showed a positive predictive value of 92.1% in a recent panel of 21 breast cancer genomes 20 . We further used a panel of DNA from 250 in-house unmatched normal samples to screen out variants in regions characterized by common sequencing artifacts. Variants present in five or more unmatched samples at a variant allele fraction greater than 5% were removed from the data set.
V(D)J score calculations. RSS motifs were scanned using a positionweight matrix (PWM) with weights taken from an RSS conservation table as reported 17 . Pseudocounts of 1 were used, and log 2 likelihood scores for the PWM were calculated using the background model of a 20% background rate for C/G and a 30% rate for A/T. Spacer lengths were scored using log 2 (relative affinity/optimal affinity), with the affinity values taken from Hesse et al. 17 . The experimental distribution of resection lengths (number of bases deleted before the final rearrangement join) were collated from real resection data from published studies 9, 16, 18 . Spacer lengths of 9-13 bp were allowed for 12-mer spacers and spacer lengths of 20-25 bp were allowed for the 23-mer spacers. Resection lengths of −1 to −50 were allowed, and, under the null where s i,j is the amount of DNA within the binding sites of chromatinbinding protein j identified by ENCODE as having chromatin state i. Assuming a Poisson distribution, the probability that the observed number of rearrangements within the binding sites of a CBP, r j,obs , was greater than expected by chance was then given by P r E r P E r r j j j j ( ,
, obs > Poisson( obs) = >
Analysis was separately performed on all rearrangement breakpoints and on rearrangement breakpoints with a RAG signature. For CBPs with technical replicates, we evaluated each replicate individually as well as a more stringent subset comprising an intersect of the two technical replicates. FDRs were calculated using the Benjamini-Hochberg procedure 55 , after which H3K4me3 was the only CBP found to have an enrichment of rearrangements within its binding sites.
Single-cell labeling, flow sorting and analysis. Patient samples were thawed from liquid nitrogen-stored cryovials and stained using carboxyfluorescin diacetate, succinimidyl ester (CFSE). CFSE is a cell viability tracer that passively diffuses into cells and only fluoresces once intracellular esterases cleave the acetyl groups from the compound. Single-cell sorting was performed on a BD FACSAria1-SORP instrument equipped with an automated cell deposition unit using the following settings: 100-micron nozzle, 1.4 bar sheath pressure, 32.6 kHz head drive and a flow rate that gave 1-200 events/s. Cell selection by forward-scattered light (FSC) and side-scattered light (SSC) accounted for cell size and internal complexity, allowing accurate selection of single cells and avoiding doublets and clumps. This novel approach for single-cell multiplex quantitative PCR (qPCR) analysis was followed according to a protocol we developed 30 . Briefly, single cells were sorted directly into lysis buffer and were lysed. Specific (DNA) target amplification (STA) was then performed before qPCR. This multiplex STA reaction involves the simultaneous amplification of all target regions of interest using custom-designed TaqMan assays for case-specific mutations. Genotyping assays for the mutations of interest were custom designed according to the manufacturer's guidelines. The STA product was then diluted before qPCR interrogation using the 96.96 dynamic microfluidic array and BioMark HD (Fluidigm) as recommended by the manufacturer.
V(D)J analysis.
To determine the status of V(D)J recombination for the samples in this study, we used the 21 BIOMED-2 primers 56 , and, for each sample in the study, we performed 20 independent PCRs. PCR analysis corresponding to the V(D)J segments with the brightest band were independently validated with a second PCR using the reaction conditions detailed in the BIOMED-2 protocol.
